Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Nevada Business Herald.
Press releases published on August 13, 2025

Roadzen Reports Best Fiscal Q1 in Company History with 22% Revenue Growth, 92% Lower Net Loss, and 50% Adjusted EBITDA Improvement Over the Same Quarter Last Year
1. Record Fiscal Q1 Revenue Sets Stage for the Year Ahead First quarter fiscal 2026 revenue increased 22% to $10.9 million from $8.9 million last year – the strongest first quarter revenue on record for Roadzen, driven by growth in India and the U.S., …

HeartCore Reports Financial Results for Second Quarter and Six Months Ended June 30, 2025
NEW YORK and TOKYO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or the “Company”), a leading enterprise software and consulting services company based in Tokyo, reported financial results for the second quarter …

Noodles & Company Announces Second Quarter 2025 Financial Results
BROOMFIELD, Colo., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Noodles …

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster …

Coherent Corp. Reports Fourth Quarter and Full Year Fiscal 2025 Results
FY25 REVENUE OF $5.81B, INCREASED 23% Y/Y FY25 GAAP GROSS MARGIN OF 35.2%, INCREASED 424 bps Y/Y; FY25 NON-GAAP GROSS MARGIN OF 37.9%, INCREASED 358 bps Y/Y FY25 GAAP LOSS OF $0.52, IMPROVED $1.32 Y/Y; FY25 NON-GAAP EPS OF $3.53, IMPROVED $2.32 Y/Y …

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 CHAPEL HILL, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE …

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial …

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates
Business highlights include: Adult NEUTRALIZE-AKI trial enrolls 31 new patients, now over 60% enrolled Three new top-rated children’s hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI) Positive survival results reported …

The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance
CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months …

Barfresh Announces Second Quarter 2025 Results
Revenue Increased 11% Year-Over-Year to $1.6 Million for Second Quarter 2025 Achieved Gross Margin of 31% for Second Quarter 2025 New Co-Manufacturer Completes Equipment Installation at End of Second Quarter 2025 and Commences Increased Supply for Third …

STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
HORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of …

Hyperfine, Inc. Reports Second Quarter 2025 Financial Results
GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the …

Global Crossing Airlines Reports Second Quarter 2025 Financial Results
GAAP Net Income of $0.6 Million or $0.01 per Share; EBITDAR1 of $19.8 Million Generated Record Block Hours of 8,065 in Q2 MIAMI, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Global Crossing Airlines Group, Inc. (Cboe CA: JET, Cboe CA: JET.B, OTCQB: JETMF) (the “ …

Highview Merger Corp. Announces Completion of $230,000,000 Initial Public Offering
Delray Beach, FL, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Highview Merger Corp. (the “Company”) announced today the closing of its initial public offering of 23,000,000 units, including 3,000,000 units sold pursuant to the full exercise of the underwriter’s over …

Fossil Group, Inc. Announces ABL Refinancing and Transaction Support Agreement for Debt Exchange
RICHARDSON, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Fossil Group, Inc. (NASDAQ: FOSL) (“Fossil” or the “Company”) today announced that it has refinanced its ABL and entered into a Transaction Support Agreement providing for an exchange of its outstanding …

Glass House Brands Reports Second Quarter 2025 Financial Results
Results surpassed expectations across key metrics including biomass production, revenue, gross profit, and Adjusted EBITDA Wholesale biomass production was 230,748 pounds, up 54% year-over-year Cost of production was $91 per pound, a substantial …

Five Below, Inc. Announces Second Quarter 2025 Earnings Release and Conference Call Date
PHILADELPHIA, PA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Five Below, Inc. (NASDAQ: FIVE), the trend-right, high-quality, extreme-value retailer for tweens, teens and beyond, today announced that its financial results for the second quarter of fiscal 2025 will …

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update
–Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026– –Completed enrollment in Phase 2b LUMUS clinical trial for envudeucitinib in systemic lupus …

The Oncology Institute Announces Changes to Board of Directors
CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Richard Barasch will retire from his role as Chairman of the …

Xos Hits New Milestones in Q2 2025 with Highest Revenue and Deliveries in the Company’s History
Reduced year-over-year operating expenses by $4.7 million and posted lowest operating loss as a public company in the second quarter of 2025 Generated positive net cash provided by operating activities of $4.6 million in the second quarter of 2025 LOS …